Estamos no ar no ! Saiba mais

Tango Therapeutics

TNGX

Valor de mercado US$ 3,72 bi

22,04 USD

-0,66

2,91%

No fechamento Atualizado 16 de out. 16:00 EDT

Pré-mercado

Após o fechamento do mercado

22,04

0,00

0%

1 dia

-2,91%

5 dias

-6,49%

1 mês

-5,61%

3 meses

-20,26%

6 meses

-11,98%

No acumulado do ano

146,81%

1 ano

140,35%

5 anos

68,24%

10 anos

115,44%

Sobre: Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Funcionários: 137

Saúde Biotecnologia

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 33,3%

Neutro 44,4%

Negativo 22,2%

Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026

Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET

Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026

Zacks Investment Research

Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock?

Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeutics or the Company) today announced that, effective September 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 146,500 shares of its common stock and 40,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan.

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 AM EDT.

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Tango Therapeutics: Promising Early Data, But A Long Road Ahead

Vopimetostat's combination with daraxonrasib has produced an unusually strong early pancreatic-cancer signal, but the evidence still comes from a very small, previously treated cohort. A planned front-line Phase 3 trial could substantially expand the opportunity, although its final design, timing, and regulatory path remain unsettled. Additional combination, lung-cancer, and CNS readouts should show whether TNGX is building a broader PRMT5 franchise or relying too heavily on one early dataset.

Tango Therapeutics: Promising Early Data, But A Long Road Ahead

Zacks Investment Research

TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses

Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.

TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses

Tango Therapeutics Announces Executive Chair Transition

BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Dr. Barbara Weber, the Executive Chairman of the Board of Directors of Tango Therapeutics, will be stepping down in connection with other pursuits.

Tango Therapeutics Announces Executive Chair Transition

Zacks Investment Research

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Zacks Investment Research

How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%

The average of price targets set by Wall Street analysts indicates a potential upside of 49.5% in Tango Therapeutics (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%

Zacks Investment Research

Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?

Tango Therapeutics' strong 2026 rally reflects promising clinical progress, but its premium valuation puts upcoming study results at the center of the next move.

Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™